Is 'off-protocol' chemotherapy for androgen-independent carcinoma of prostate warranted?

Sridhar Mani, N. J. Vogelzang

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

It is acceptable to treat HRPC patients with off-protocol chemotherapy if these patients do not accept protocol therapy or are ineligible for such therapy. The choice of cytotoxic agent needs to be individually assessed, depending on range of tolerable toxicities and personal preferences of the physician and patient. At the present time, single-agent therapy with oral or intravenous cyclophosphamide or mitoxantrone/prednisone may offer optimal palliation without undue side effects in a predictable number of patients.

Original languageEnglish (US)
Pages (from-to)749-768
Number of pages20
JournalHematology/Oncology Clinics of North America
Volume10
Issue number3
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Androgens
Prostate
Carcinoma
Drug Therapy
Mitoxantrone
Patient Preference
Cytotoxins
Prednisone
Cyclophosphamide
Therapeutics
Physicians

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Is 'off-protocol' chemotherapy for androgen-independent carcinoma of prostate warranted? / Mani, Sridhar; Vogelzang, N. J.

In: Hematology/Oncology Clinics of North America, Vol. 10, No. 3, 1996, p. 749-768.

Research output: Contribution to journalArticle

@article{3d5b7c6bc6384d728b55a5a751ada75d,
title = "Is 'off-protocol' chemotherapy for androgen-independent carcinoma of prostate warranted?",
abstract = "It is acceptable to treat HRPC patients with off-protocol chemotherapy if these patients do not accept protocol therapy or are ineligible for such therapy. The choice of cytotoxic agent needs to be individually assessed, depending on range of tolerable toxicities and personal preferences of the physician and patient. At the present time, single-agent therapy with oral or intravenous cyclophosphamide or mitoxantrone/prednisone may offer optimal palliation without undue side effects in a predictable number of patients.",
author = "Sridhar Mani and Vogelzang, {N. J.}",
year = "1996",
doi = "10.1016/S0889-8588(05)70365-8",
language = "English (US)",
volume = "10",
pages = "749--768",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Is 'off-protocol' chemotherapy for androgen-independent carcinoma of prostate warranted?

AU - Mani, Sridhar

AU - Vogelzang, N. J.

PY - 1996

Y1 - 1996

N2 - It is acceptable to treat HRPC patients with off-protocol chemotherapy if these patients do not accept protocol therapy or are ineligible for such therapy. The choice of cytotoxic agent needs to be individually assessed, depending on range of tolerable toxicities and personal preferences of the physician and patient. At the present time, single-agent therapy with oral or intravenous cyclophosphamide or mitoxantrone/prednisone may offer optimal palliation without undue side effects in a predictable number of patients.

AB - It is acceptable to treat HRPC patients with off-protocol chemotherapy if these patients do not accept protocol therapy or are ineligible for such therapy. The choice of cytotoxic agent needs to be individually assessed, depending on range of tolerable toxicities and personal preferences of the physician and patient. At the present time, single-agent therapy with oral or intravenous cyclophosphamide or mitoxantrone/prednisone may offer optimal palliation without undue side effects in a predictable number of patients.

UR - http://www.scopus.com/inward/record.url?scp=0029952543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029952543&partnerID=8YFLogxK

U2 - 10.1016/S0889-8588(05)70365-8

DO - 10.1016/S0889-8588(05)70365-8

M3 - Article

VL - 10

SP - 749

EP - 768

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 3

ER -